Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.

By M. Miettinen, W. El-Rifai, Leslie H L Sobin, J. Lasota. Human Pathology, 2002

688 citations recorded by the source corpus.

Subfields: Gastroenterology, Neurology, Surgery

View Paper: https://www.semanticscholar.org/paper/952f5e9a4420693605948b923a6b2df2acffe443

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Rey
2. A. Malet
3. A. Darnell
4. C. Pericay
5. J. Martin
6. E. Musulen
7. E. Dalmau
8. E. Saigí

Citations in the corpus

• Gastrointestinal stromal tumors (2006, background): “The availability of the new tyrosine kinase inhibitor drug, STI-571 (imatinib), for the treatment of metastatic GISTs may shift the focus of prediction of malignancy to the proper selection of patients for this new adjuvant therapy [26].”
• Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era (2005, neutral): “5); Int: 55 (19); H: 60 (21); OM: 29 (10)”